My ePortfolio Register   

SABCS 2016 /
Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer

6th - 10th Dec 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.16
Views: 360
Rating:

Dr Terry Mamounas - UF Health Center, Orlando, USA

Dr Mamounas speaks with ecancertv at SABCS 2016 about the impact of letrozole treatment up to, and beyond, 5 years on disease free survival of post-menopausal women with HR positive breast cancer who have completed previous adjuvant aromatase inhibitory therapy.

From nearly 4000 patients enrolled, he describes a reduction in the that of distant recurrent disease and improvement in breast cancer free interval events, though notes that overall benefits on DFS did not meet statistical significance.

Dr Mamounas also notes an elevated risk of thrombotic events after 2.5 for patients receiving letrozole past that point.

These results were first presented at a press conference session, with video coverage here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence